Filing Flows › Arbutus Biopharma (ABUS) › Q2 2025
Arbutus Biopharma (ABUS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Arbutus Biopharma (ABUS) reported revenue of $10.7M for the second quarter 2025 (Q2 2025), +522% from a year earlier and +509% from the quarter before. Operating margin was 13.9%, net earnings $2.5M (23.5% of revenue).
Arbutus Biopharma, Q2 2025: revenue $10.7M (+522% year over year), operating margin 13.9%, net earnings $2.5M, operating cash flow −$15.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.7M | +509% | +522% |
| Operating profit | $1.5M | — | — |
| Net earnings | $2.5M | — | — |
| Operating cash flow | −$15.7M | — | — |
What changed
Revenue was $10.7M in Q2 2025, up 522% year over year and up 509% from the previous quarter. Collaborations and licenses was the largest line at 95% of revenue. Collaborations and licenses added $9.1M year over year (up 784%), 100% of the total change. Non-cash royalty revenue declined 8%.
Operating profit was $1.5M, a 13.9% margin (up 1264.3 points year over year). Total costs fell 60% while revenue rose 522%. The fastest-growing cost line was Other operating costs (+101%). Net earnings were $2.5M. The effective tax rate was 0.0%. Non-operating items added $1.0M, 41% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$15.7M. Non-cash charges added back $11K of depreciation and amortization and $864K of share-based compensation. Working capital and other items used $19.1M.
Questions
What was Arbutus Biopharma's revenue in the second quarter 2025?
Arbutus Biopharma (ABUS) reported revenue of $10.7M for the second quarter 2025 (Q2 2025), +522% from a year earlier and +509% from the quarter before.
Was Arbutus Biopharma profitable in the second quarter 2025?
Operating profit was $1.5M (13.9% of revenue) and net earnings $2.5M.
Source: Arbutus Biopharma 10-Q on SEC EDGAR.